NSE · ALIVUS.NS
Alivus Life Sciences Limited
₹1,433.70+₹36.30 (+2.6%)
Alivus Life Sciences Limited’s quoted price sits in the upper half of its reported 52-week range, 4.36% below the high.
Loading market information…
NSE · INDSWFTLAB.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:19 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Ind-Swift Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 12.24% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Ind-Swift Laboratories Limited’s forward annual dividend is ₹1.00 per share, paid annual. The forward yield is 0.27% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Ind-Swift Laboratories Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Ind-Swift Laboratories Limited, an Indian enterprise, is engaged in the development, production, and distribution of active pharmaceutical ingredients (APIs). The company's comprehensive API portfolio addresses numerous therapeutic domains, including macrolide antibiotics, cardiovascular ailments, antihistamines, antidiabetics, antipsychotics, bone resorption inhibitors, antimigraine treatments, Parkinson's disease, hyperparathyroidism, analgesics, aromatase inhibitors, nootropics, antidiarrhoeal/antiprotozoal conditions, anticholinergics, sedatives, hypnotics, alcohol abstinence, antineoplastics, and solutions for ADHD symptoms. Additionally, Ind-Swift supplies reference standards and impurities for a long list of specific compounds such as acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. Beyond its core manufacturing operations, the company offers a broad spectrum of services. These encompass early and late-phase drug development, process research and development, contract and API manufacturing, custom chemicals and synthesis, analytical development, regulatory support, specialized chemistry services, impurity profiling, isolation, discovery, identification, characterization, and project management. Founded in 1995, and headquartered in Manimajra, India, Ind-Swift Laboratories Limited also exports its products internationally.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,433.70+₹36.30 (+2.6%)
Alivus Life Sciences Limited’s quoted price sits in the upper half of its reported 52-week range, 4.36% below the high.
₹897.00-₹30.65 (-3.3%)
Aarti Pharmalabs Limited’s quoted price sits in the upper half of its reported 52-week range, 10.51% below the high.
₹179.24-₹5.69 (-3.08%)
IOL Chemicals and Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 19.98% below the high.
₹508.70+₹22.90 (+4.71%)
SMS Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 3.15% below the high.
₹443.05-₹5.95 (-1.33%)
Aarti Drugs Limited’s quoted price sits in the upper half of its reported 52-week range, 17.15% below the high.
₹214.50+₹10.10 (+4.94%)
Hikal Limited’s quoted price sits in the upper half of its reported 52-week range, 17.82% below the high.
₹2,593.30-₹19.50 (-0.75%)
NGL Fine-Chem Limited’s quoted price sits in the upper half of its reported 52-week range, 28.0% below the high.
₹307.00-₹5.85 (-1.87%)
Bajaj Healthcare Ltd’s quoted price sits in the lower half of its reported 52-week range, 37.21% below the high.
